- Advertisement -
- Advertisement -

Rhenman & Partners Boosts Biopharma Expertise

- Advertisement -

Stockholm (HedgeNordic) – Rhenman & Partners is expanding its five-person investment team with the hiring of Amennai Beyeen as a biopharma analyst. He joins from global healthcare company Novartis.

“We are very happy to welcome Amennai to Rhenman & Partners,” says Henrik Rhenman, co-founder and CIO at Rhenman & Partners. “Amennai’s strong background and competence from the world of research, and his experience of pharmaceutical companies where he has been able to closely follow processes from idea to finished product make him a very good addition to our investment team.”

“We are very happy to welcome Amennai to Rhenman & Partners.”

Amennai Beyeen has worked for about 12 years at Novartis, focusing on the development and launch of new drugs. He also holds a doctorate in neuroimmunology from Karolinska Institutet in Stockholm. Beyeen will join the five-person investment team running the healthcare-focused equity hedge fund Rhenman Healthcare Equity L/S. He will have a particular focus on biopharma companies and the development of new drugs and treatments.

“It is very exciting to start at Rhenman & Partners,” Amennai Beyeen comments on joining the Swedish healthcare-focused asset manager. “I am extremely impressed by the team’s deep knowledge of the healthcare sector as well as the fund’s versatile investment process, which is reflected in its strong results over the years,” he continues. “I look forward to joining this competent team and contributing with my experience from the life science sector.”

Rhenman & Partners Asset Management has been running its long-biased equity hedge fund with an exclusive focus on healthcare since mid-2009, delivering an annualized return of 17.3 percent through November 2022. The fund’s main share class (IC1 EUR) edged down 1.6 percent in the first 11 months of this year. Rhenman Healthcare Equity L/S oversees €923 million in assets under management.

Subscribe to HedgeBrev, HedgeNordic’s weekly newsletter, and never miss the latest news!

Our newsletter is sent once a week, every Friday.

Eugeniu Guzun
Eugeniu Guzun
Eugeniu Guzun serves as a data analyst responsible for maintaining and gatekeeping the Nordic Hedge Index, and as a journalist covering the Nordic hedge fund industry for HedgeNordic. Eugeniu completed his Master’s degree at the Stockholm School of Economics in 2018. Write to Eugeniu Guzun at eugene@hedgenordic.com

Latest Articles

The Narrative Has Shifted

Stockholm (HedgeNordic) – Stock markets globally lost ground for three consecutive months starting in August, only to witness a recovery in November. Following a...

Global Assets Founder Shifts Focus

Stockholm (HedgeNordic) – Lars Semb Maalen-Johansen, the responsible fund manager of Global Assets Dynamic under the umbrella of Global Assets, is bidding farewell to...

Case Hedgefond Building Stability and Momentum

Stockholm (HedgeNordic) – Case Hedgefond, once a billion-dollar fund in the Nordic hedge fund industry, has undergone a restructuring process since being taken over...

Ex-QQM Duo Unveils Funds Under Meriti Umbrella

Stockholm (HedgeNordic) – Ola Björkmo and Jonas Sandefeldt, known for developing the systematic market-neutral strategy behind QQM Equity Hedge, are spearheading the launch of...

Trend-Following and Long/Short Quality: Attack Wins You Games, Defence Wins You Titles

By Yash Panjabi and Graham Robertson – Man AHL: How can we protect against sharper, faster sell-offs? Or, better yet, how can we profit...

Asilo Argo’s Strong November Rally

Stockholm (HedgeNordic) – Despite enduring three straight losing months since August in tandem with broader stock markets, Asilo Argo is currently enjoying one of...

Allocator Interviews

Latest Articles

Man Institute Insights


Request for Proposal

- Advertisement -